- CEO
- Shigeyuki Kawamura
- Full Time Employees
- 5,946
- Sector
- Basic Materials
- Industry
- Chemicals
- Address
- Meiji Yasuda Seimei Building Tokyo TY Japan 100-0005
- IPO Date
- Aug 3, 2012
- Business
- Nippon Kayaku Co., Ltd. Nippon Kayaku Co., Ltd. develops, manufactures and markets functional chemicals, pharmaceuticals, safety systems and agrochemicals across Japan, Asia, Europe and other international markets; founded in 1916 and headquartered in Tokyo, Japan. The Functional Chemicals segment provides epoxy resins and UV-curable resins for semiconductors and displays, photoresists and insulating materials for microelectromechanical systems, inkjet colorants, textile and paper dyes, catalysts for acrylic acid production, polarizing films, liquid crystal components and x-ray analysis parts; the Pharmaceuticals segment offers anti-cancer agents including ROS1 inhibitors, biosimilars, generic drugs, interventional radiology products, cardiovascular drugs, bulk drug intermediates and diabetes markers like GlycoMark; the Safety Systems segment supplies airbag inflators for driver, passenger, side, curtain and knee applications, micro gas generators for seatbelt pretensioners and squibs; the Agrochemicals segment delivers insecticides, herbicides, soil fumigants and sanitary insecticides. In August 2025, the company executed a shareholders agreement with Formiica Pharmaceuticals Pte. Ltd. and CBC Co., Ltd. to establish a Singapore-based joint venture for in-licensing and sublicensing pharmaceuticals into Asia including Japan and Oceania, granting Nippon Kayaku preferential rights for Japanese development and sales; in November 2025, it launched IBTROZI Capsules 200mg, an oncology drug for ROS1 fusion-positive non-small cell lung cancer exclusively licensed from Nuvation Bio Inc., following national health insurance listing; additionally in November 2024, it initiated a share buyback of up to 6.5 million shares for 7.0 billion yen to boost capital efficiency.